Breaking News

Upperton Invests £5M in New Sterile Manufacturing Facility

Will use advanced VHP isolation technology and carry out GMP fill-finish of sterile drug products for biologics and small molecules.

Upperton Pharma Solutions, a contract development and manufacturing organization (CDMO), reported a £5 million investment to expand operations into small-scale sterile fill-finish. After completion of a new 50,000 sq.-ft. GMP facility in 2023, the UK-based company will expand its Trent Gateway site to include sterile capabilities with a purpose-built facility designed specifically in line with the revised EU GMP Annex-1 regulations. Construction of the facility will begin this February and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters